First-in-human single and multiple ascending dose testing of MT-251 in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind, placebo-controlled Phase 1 trial will give single and multiple ascending doses of MT-251 to healthy volunteers to characterize safety, tolerability, pharmacokinetics, and immunogenicity. Participants will be randomized to receive MT-251 or placebo and will undergo serial clinical assessments, lab testing, ECGs, and blood sampling for PK and antibody responses. Dose escalation decisions will be based on safety and tolerability data from earlier cohorts. The results will guide dose selection and design for subsequent patient trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female participants between 19 and 55 years of age (inclusive) at the time of signing informed consent.
2. Female participants must be of nonchildbearing potential, defined as postmenopausal or surgically sterile, and have official documentation, at least 6 months prior to the first dose.
3. Male subjects must use highly effective forms of contraception during sexual intercourse with female partners of childbearing potential. A non-vasectomized, male subject must agree to use a condom with a chemical barrier method.
4. Continuous non-smoker who has not used tobacco or nicotine-containing products for at least 3 months prior to the first dose of drug.
5. Good general health.
6. Able to provide written informed consent and understand and comply with the requirements of the study.

Exclusion Criteria:

1. History or presence of any clinically significant organ system disease.
2. Abnormal laboratory assessments, physical exam of ECG outside the normal range that is judged by the Investigator to be clinically significant.
3. History of alcohol or drug abuse within the past 24 months.
4. Current use or history of regular tobacco or nicotine-containing products within 3 months prior to screening.
5. Administration of any prescription drug within 21 days or 5 half-lives (whichever is longer) of study drug administration; or over-the-counter drug within 7 days or 5 half-lives (whichever is longer) of study drug administration.
6. Administration or use of any investigational drug or device within 30 days preceding the first does of study drug administration.
7. Blood donation within 60 days prior to dosing or plasma donation within 14 days prior to dosing.
8. Sensitivity to any of the study drugs, or components thereof, or drug or other allergy that in the opinion of the Investigator or Sponsor Medical Monitor, contraindicates participation in the study.

Where it's running

• Mirador Clinical Department
  San Diego, California, United States Recruiting

Study contacts

• Study coordinator: Toll-Free Number
• Email: clinicaltrials@miradortx.com
• Phone: 844-206-4980

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of Exercise Snacks on Muscle Size and Strength in Healthy Young Adults

  This study tests whether many small workouts throughout the week can build muscle size and improve strength in healthy, untrained young adults compared with the usual twice-weekly workouts.

  Recruiting University of British Columbia · Vancouver, British Columbia · NCT07760597

• ORX489 safety and dosing in healthy adults ages 18 to 60

  This will test whether ORX489 tablets are safe, well tolerated, and how they are processed in the body in healthy men and women aged 18 to 60.

  Recruiting Phase 1 Centessa Pharmaceuticals (UK) Limited · Lincoln, Nebraska · NCT07413666

• ReHIIT Prehabilitation in Healthy Adults

  This pilot tests a combined resistance and high‑intensity interval training program to establish baseline physiology in healthy adults before applying findings to cancer patients.

  Recruiting University of Nottingham · Derby, Derbyshire · NCT07313332

• Safety and drug levels of a 3‑month naltrexone implant (BICX104) with or without bupropion versus monthly Vivitrol injections

  This will test whether a three‑month naltrexone implant (BICX104), given alone or with extended‑release bupropion, is safe and keeps steady drug levels compared with monthly Vivitrol injections in healthy adults.

  Recruiting Phase 1 BioCorRx Pharmaceuticals Inc · Miami, Florida · NCT07269873

• Compare two forms and doses of vonafexor and see if the high dose interacts with other drugs

  This test looks at how two doses and two formulations of vonafexor (EYP651 and vonafexor acid) are absorbed and processed in healthy adults and whether the high dose interacts with common medicines.

  Recruiting Phase 1 Enyo Pharma · Gières · NCT07251153

• Low-frequency vibrating mat for sleep and daily stress recovery

  This test will see if using a low-frequency vibrating mat at home for three weeks improves stress recovery, sleep quality, mood, and attention in healthy adults aged 18-45.

  Recruiting Florida International University · Miami, Florida · NCT07221318

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.